Ophthalmology Times Europe

Get a breakdown of the key steps in implanting the port delivery system in the next part of our series on novel retinal disease treatment. Aleksandra Rachitskaya, MD; and Jordan Graff, MD, FACS, discuss the whole process, emphasizing incision and closure techniques. Click here to watch now: https://ow.ly/oaZJ50V4EwH #portdeliverysystem #retinaldiseases

If you're attending the The European Society of Cataract and Refractive Surgeons (ESCRS) Winter Meeting this weekend, make sure you check out the TOGA sessions and visit the world café—two items on our must-see list. https://lnkd.in/enHsJPKA

Patients experiencing a high treatment burden with frequent anti-VEGF injections every 4 to 8 weeks are optimal candidates for the port delivery system. Learn how patients are selected for this treatment option and discover how it can reduce the number of clinic visits while maintaining therapeutic effectiveness. Click here to watch now: https://ow.ly/2Yt050UTiik #antiVEGF #retinaldiseases #treatmentburden

Our journey with Aleksandra Rachitskaya, MD; and Jordan Graff, MD, FACS, continues as they dive deeper into retinal disease treatment. In this series installment, learn how successfully implementing the port delivery system requires careful attention to surgical techniques that differ significantly from standard intravitreal injections. Click here to watch now: https://ow.ly/ne3S50V4EhT #surgical #retinaldiseases

Sponsored by Hoya Vision Care. Hoya Vision Care is committed to evolving treatment solutions, to allow more and more myopic children to take advantage of effective and innovative care, ensuring better vision outcomes. That’s why they introduced a broader power range of MiYOSMART clear spectacle lenses, accommodating prescriptions up to −13.00D. With this extended power range, MiYOSMART spectacle lenses can better serve myopic patients with high prescriptions and meet their diverse needs more effectively. Take the first step towards better vision for children. Visit https://ow.ly/r8iN50V32Rz to discover how MiYOSMART spectacle lenses can make a difference. #ad #MiYOSMART #HighMyopia #HOYAVisionCare

Join Aleksandra Rachitskaya, MD, and Jordan Graff, MD, FACS, as they continue exploring novel treatments for retinal diseases. Discover how the port delivery system with ranibizumab represents a paradigm shift in neovascular age-related macular degeneration treatment and learn how it can be a preferred alternative to frequent intravitreal injections while ensuring consistent therapeutic levels. Click here to watch now: https://ow.ly/kmrP50UTie9 #ranibizumab #AMD #retinaldiseases

Navigating complex cataract and clear lens exchange (CLE) cases requires precision and confidence. This month, Patricia Casaer, MD, and Tobias Gutzeit, BSc, delve into the ZEISS IOL Power Calculation Service (IPCS) and its role in achieving a spectacles-free outcome for a patient with presbyopia and high hyperopic astigmatism. Read the full case study here: https://ow.ly/G36050USxzU #Cataracts #PatientOutcomes #ClearLensExchange

The next wave of innovation in retinal care is here. Join leading specialists as they break down: ✔️ Aflibercept 8 mg’s higher molar dose and its impact on treatment durability ✔️ PULSAR & PHOTON trial findings and extended dosing insights ✔️ Patient selection strategies for maximizing efficacy ✔️ Faricimab’s dual-action approach to tackling inflammation and vascular instability Watch Episodes 5-8 now! https://ow.ly/9HE150V0wAW

How are new treatment strategies changing retinal disease management? Find out in our newest expert panel series, covering key topics: ✅ The latest anti-VEGF advancements ✅ Aflibercept 8 mg & faricimab insights ✅ Real-world data & clinical applications Don’t miss these critical discussions—watch now! https://ow.ly/2nZB50V0v3m

Mariya Moosajee is a professor of molecular ophthalmology at University College London, and a consultant ophthalmologist specialising in genetic eye disease at Moorfields Eye Hospital, London, UK. She is also the creator of Gene Vision (www.gene.vision), a free, accessible and comprehensive web resource for patients and clinicians who need information on genetic eye disease. Funding from the National Institute for Health and Care Research and Retina UK has enabled Prof Moosajee and her colleagues to construct a website with a full suite of accessibility options for visually impaired patients. In this interview from our February issue, Prof Moosajee reflected on the growth Gene Vision has seen since its 2020 launch and the future of the project. https://lnkd.in/eKVfZBGB